Gilead and partner Arcellx released pivotal‑stage data showing 96% tumor response and 74% complete remission rates for anito‑cel in multiple myeloma, with durable responses and no new safety signals. The trial enrolled 117 patients and the companies presented the latest analysis at ASH. Kite/Gilead executives signaled readiness to launch anito‑cel as a challenger to existing myeloma CAR‑T products, positioning the program as critical amid slowing sales of prior Gilead CAR‑T assets. The data intensify competition in multiple myeloma cell therapy and will shape regulatory and commercial sequencing for next‑generation CAR‑T approvals.